BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 15918557)

  • 1. [Pathologic characteristics and evaluation of the pancreatic cancer].
    Fukushima N; Mukai K
    Gan To Kagaku Ryoho; 2005 May; 32(5):599-604. PubMed ID: 15918557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
    Adsay NV; Basturk O; Cheng JD; Andea AA
    Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current understanding of precursors to pancreatic cancer.
    Takaori K
    J Hepatobiliary Pancreat Surg; 2007; 14(3):217-23. PubMed ID: 17520195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current topics on precursors to pancreatic cancer.
    Takaori K; Hruban RH; Maitra A; Tanigawa N
    Adv Med Sci; 2006; 51():23-30. PubMed ID: 17357272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach.
    Katabi N; Klimstra DS
    J Clin Pathol; 2008 Dec; 61(12):1303-13. PubMed ID: 18703569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic tumors with cystic dilatation of the ducts: intraductal papillary mucinous neoplasms and intraductal oncocytic papillary neoplasms.
    Adsay NV; Longnecker DS; Klimstra DS
    Semin Diagn Pathol; 2000 Feb; 17(1):16-30. PubMed ID: 10721804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.
    Wilentz RE; Iacobuzio-Donahue CA; Argani P; McCarthy DM; Parsons JL; Yeo CJ; Kern SE; Hruban RH
    Cancer Res; 2000 Apr; 60(7):2002-6. PubMed ID: 10766191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histologic characteristics of pancreatic intraepithelial neoplasia associated with different pancreatic lesions.
    Recavarren C; Labow DM; Liang J; Zhang L; Wong M; Zhu H; Wang J; Francis F; Xu R
    Hum Pathol; 2011 Jan; 42(1):18-24. PubMed ID: 21056895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucin expression profile in pancreatic cancer and the precursor lesions.
    Nagata K; Horinouchi M; Saitou M; Higashi M; Nomoto M; Goto M; Yonezawa S
    J Hepatobiliary Pancreat Surg; 2007; 14(3):243-54. PubMed ID: 17520199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathological aspects of pancreatic cancer].
    Egawa S; Sunamura M; Abe H; Motoi F; Fukuyama S; Matsuno S
    Gan To Kagaku Ryoho; 2005 May; 32(5):605-11. PubMed ID: 15918558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
    Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
    Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types.
    Ban S; Naitoh Y; Mino-Kenudson M; Sakurai T; Kuroda M; Koyama I; Lauwers GY; Shimizu M
    Am J Surg Pathol; 2006 Dec; 30(12):1561-9. PubMed ID: 17122512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
    Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
    J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of fine needle aspiration cytology for the distinction of pancreatic mucinous neoplasia.
    Stelow EB; Shami VM; Abbott TE; Kahaleh M; Adams RB; Bauer TW; Debol SM; Abraham JM; Mallery S; Policarpio-Nicolas ML
    Am J Clin Pathol; 2008 Jan; 129(1):67-74. PubMed ID: 18089490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas.
    Sasaki S; Yamamoto H; Kaneto H; Ozeki I; Adachi Y; Takagi H; Matsumoto T; Itoh H; Nagakawa T; Miyakawa H; Muraoka S; Fujinaga A; Suga T; Satoh M; Itoh F; Endo T; Imai K
    Oncol Rep; 2003; 10(1):21-5. PubMed ID: 12469138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precursor lesions in pancreatic cancer: morphological and molecular pathology.
    Scarlett CJ; Salisbury EL; Biankin AV; Kench J
    Pathology; 2011 Apr; 43(3):183-200. PubMed ID: 21436628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetics of intraductal papillary-mucinous neoplasms of the pancreas.
    Furukawa T
    J Hepatobiliary Pancreat Surg; 2007; 14(3):233-7. PubMed ID: 17520197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas.
    Riall TS; Stager VM; Nealon WH; Townsend CM; Kuo YF; Goodwin JS; Freeman JL
    J Am Coll Surg; 2007 May; 204(5):803-13; discussion 813-4. PubMed ID: 17481488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Precursors to pancreatic cancer].
    Søreide K; Immervoll H; Molven A
    Tidsskr Nor Laegeforen; 2006 Mar; 126(7):905-8. PubMed ID: 16554881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic intraepithelial neoplasia revisited and updated.
    Sipos B; Frank S; Gress T; Hahn S; Klöppel G
    Pancreatology; 2009; 9(1-2):45-54. PubMed ID: 19077454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.